SCHEMBL22017690

SCHEMBL22017690

CC(C)n1c(=O)c2ncccc2n(C)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.45
ADORA3 P0DMS8 2/20 0.41
ADORA2A P29274 2/20 0.41
ADORA1 P30542 1/20 0.41
ADORA2B P29275 1/20 0.41
FEN1 P39748 1/20 0.39
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CMA1 P23946 2/20 0.37
BRD4 O60885 2/20 0.36
BRPF1 P55201 2/20 0.36
MAPK14 Q16539 2/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13819108 0.83 ADORA2A (0.53) GRM4ADORA3ADORA2AADORA1FEN1
SCHEMBL22038880 0.82 ADORA2B (0.45) GRM4ADORA2BFEN1ALDH1A1HTT
SCHEMBL13322658 0.79 FEN1 (0.46) GRM4ADORA2BFEN1ALDH1A1HTT
SCHEMBL22016242 0.76 GRM4 (0.44) GRM4ADORA3ADORA2AADORA1FEN1
SCHEMBL23471416 0.75 KAT2B (0.36) GRM4ADORA3ADORA2AADORA1FEN1
SCHEMBL16640322 0.75 MAPT (0.41) ADORA3ADORA2AALDH1A1HTTSMN1; SMN2
SCHEMBL22017688 0.74 FEN1 (0.65) GRM4ADORA2BFEN1ALDH1A1
SCHEMBL12139324 0.73 SLC6A2 (0.50) FEN1ALDH1A1SMN1; SMN2BRD4BRPF1
SCHEMBL27446553 0.73 FEN1 (0.41) ADORA2BFEN1ALDH1A1HTTSMN1; SMN2
SCHEMBL16352662 0.73 ERCC1 (0.61) GRM4FEN1ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS GILEAD SCIENCES, INC. 2022-04-21 US disclosed
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin GILEAD SCIENCES, INC. (US) 2022-01-18 US disclosed
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 GRM4 1490/4885ADORA3 2207/4885ADORA2A 2997/4885
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin ITGB7, ITGB4, ITGA4 GRM4 1490/4885ADORA3 2207/4885ADORA2A 2997/4885
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS ITGB7, ITGB1, ITGA2B GRM4 2063/4885ADORA3 1388/4885ADORA2A 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.